Proposed core set of outcome measures in patients with primary Sjögren's syndrome: 5 year follow up

J Rheumatol. 2005 Aug;32(8):1495-502.

Abstract

Objective: To clarify the spontaneous course of important disease manifestations (a core set of outcome measures) over a period of 5 years in patients with primary Sjögren's syndrome (SS), and to analyze predictors of unfavorable outcome. To test the usefulness of the recently proposed core set of outcome measures.

Methods: A cohort of patients with primary SS according to the American-European consensus criteria (AECC) (n = 58) was followed over a period of 5 years. Measures for subjective and objective disease characteristics, IgG concentrations and health related quality of life were analyzed on 2 occasions and compared.

Results: During followup, symptoms of dry eyes, dry mouth, fatigue, and health related quality of life were stable. Regarding objective signs, there was a modest but statistically significant worsening of the van Bijsterveld score. Seropositivity for anti-SSA and low complement levels predicted further decline in the van Bijsterveld score. Floor/ceiling effects in the outcome measures in the core set complicate documentation of further decline, but may allow monitoring of improvement in established primary SS.

Conclusion: Primary SS, if classified according to the strict AECC criteria, is a bothersome and slowly progressive disease, with fatigue and discomfort developing early. The proposed outcome measures may be suitable for assessing improvement in randomized controlled trials.

MeSH terms

  • Adolescent
  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Aged
  • Antidepressive Agents / therapeutic use
  • Autoantibodies / blood
  • Comorbidity
  • Diuretics / therapeutic use
  • Dry Eye Syndromes / epidemiology
  • Fatigue / epidemiology
  • Follow-Up Studies
  • Health Status*
  • Humans
  • Immunoglobulin G / blood
  • Longitudinal Studies
  • Middle Aged
  • Predictive Value of Tests
  • Quality of Life*
  • Severity of Illness Index*
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / epidemiology
  • Sjogren's Syndrome / immunology
  • Treatment Outcome
  • Xerostomia / epidemiology

Substances

  • Adrenergic beta-Antagonists
  • Antidepressive Agents
  • Autoantibodies
  • Diuretics
  • Immunoglobulin G